2021-04-08

Sedana Medical AB (publ) (Sedana Medical or the company) presents a health economic analysis at the European Conference for Health Economics and Outcomes Research 2018 (ISPOR) in Barcelona, showing clinical and economic benefits of inhaled isoflurane sedation via AnaConDa versus conventional intravenous sedation with propofol or midazolam.

Head Office Sedana … The AnaConDa (Anaesthetic Conserving Device) is an anaesthetic delivery system, developed for the administration of Isoflurane or Sevoflurane to mechanically ventilated patients. Head Office Sedana Medical AB (publ) The AnaConDa (Anaesthetic Conserving Device) is an anaesthetic delivery system, developed for the administration of Isoflurane or Sevoflurane to mechanically ventilated patients. Head Office Sedana Medical AB (publ) 2019-10-16 Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane) Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of Sedana Medical AB (publ) (SEDANA: FN Stockholm) meddelade idag att bolaget har beviljats ytterligare ett patent avseende den medicintekniska produkten AnaConDa. Tekniken som patentet skyddar möjliggör en minskning av så kallad dead space med hjälp av iläggsmaterial.

Sedana medical anaconda

Bolagets Certified Adviser är Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se. Om Sedana Medical . Sedana Medical AB (publ) utvecklar och säljer den medicintekniska produkten AnaConDa för administrering av volatila anestetika. Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients.

2021-04-08 Sedana Medical AB (publ) (Sedana Medical eller bolaget) meddelar idag att bolaget erhållit marknadsgodkännande för AnaConDa från Ministry of Health, Labour and Welfare (MHLW) i Japan. Godkännandet innebär att AnaConDa får marknadsföras, säljas och användas för administrering av flyktiga anestesiläkemedel för mekaniskt ventilerade patienter i Japan.

AnaConDa (Anaesthetic Conserving Device) ist ein Medizinprodukt für die Verabreichung von volatilen Anästhetika (Isoflurane oder Sevoflurane) an mechanisch beatmete Patienten. Hauptsitz Sedana Medical AB (publ)

128 likes · 1 talking about this. Sedana Medical, developed the AnaConDa technology which enables the safe and controlled delivery of volatile anaesthetics to invasively ventilated Sedana Medical AB (”Sedana Medical” and “the Company”) has today submitted the application for registration of the medical device AnaConDa in Japan through its Japanese distributor. AnaConDa is a patented medical device with a unique technology making it possible to sedate patients with volatile anaesthetics in intensive care units, so called inhalation sedation.

Sedana Medical AB (publ) is a Sweden-based medical technology company. It develops, markets and sales medical devices and conducts drug development for

Tyskland. Telefon: +49 (0)8171 91 13 41. Fax: +49 (0)8171 91 00 72. E-post: order.de@sedanamedical.com. Kontaktuppgifter.

Sedana Medical. 128 likes · 1 talking about this. Sedana Medical, developed the AnaConDa technology which enables the safe and controlled delivery of volatile anaesthetics to invasively ventilated Sedana Medical AB (”Sedana Medical” and “the Company”) has today submitted the application for registration of the medical device AnaConDa in Japan through its Japanese distributor. AnaConDa is a patented medical device with a unique technology making it possible to sedate patients with volatile anaesthetics in intensive care units, so called inhalation sedation.
Lunkaberg skillinge

New users can learn from the full training program. Experienced users can refresh their knowledge and learn more. Sedana Medical AB (publ) Vendevägen 89 SE-182 32 Danderyd Sverige. Telefon: 08-124 05 200 E-post: info@sedanamedical.com AnaConDa är en medicinteknisk produkt för engångsbruk för administrering av flyktiga anestesimedel (isofluran eller sevofluran) som ansluts mellan Y-stycket och endotrakealtuben. Produkten har inga elektriska komponenter och är kompatibel med magnetresonans- och datortomografi.

Tekniken används vanligen för intensivvårdspatienter vid nedsövning och skiljer sig gentemot den traditionella behandlingen som tidigare utgetts intravenöst med läkemedel. Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients.
Izakaya växjö ny restaurang

röntgenvägen 1 flemingsberg
1630 usd to sek
hur länge har man en anmärkning hos kronofogden
arsta centrum
michel montaigne pronunciation
gardeners supply

Sedana Medical is a global medical technology company. that develops, markets and sells AnaConDa, a medical device for the administration of inhaled anaesthetics to mechanically ventilated patients. Contact us

A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane). Sedana Medical ist ein schwedisches Medizintechnikunternehmen, welches 2005 nach dem Erwerb der AnaConDa Technologie.

6 Dec 2020 The anaesthetic conserving device (“AnaConDa”, Sedana Medical) is one device that delivers a safe sedative dose of either isoflurane or

AnaConDa är Sedana Medicals produkt för administrering av flyktiga anestesiläkemedel inom framförallt intensivvården och det japanska hälsoministeriets godkännande innebär att bolagets distributör nu kan påbörja försäljning av AnaConDa i Japan. Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company's medical device AnaConDa, for the administration of volatile anesthetics for sedation of mechanically ventilated intensive care patients, has received approval for use on children by the European notifying body BSI Group.

The approval also means that AnaConDa can be used in patients with severely impaired lung capacity. Sedana Medical AB (publ) (Sedana Medical or the company) presents a health economic analysis at the European Conference for Health Economics and Outcomes Research 2018 (ISPOR) in Barcelona, showing clinical and economic benefits of inhaled isoflurane sedation via AnaConDa versus conventional intravenous sedation with propofol or midazolam. AnaConDa from Sedana Medical reviewed by NICE in UK Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the UK's National Institute for Health and Care Excellence (NICE) has issued Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients.